Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A randomized, blinded, placebo-controlled study assessing the impact of health and wellness products on pain and other health outcomes
This is a randomized, blinded, placebo-controlled study conducted with up to 300 adult participants per study arm, age 21 and older and residing in the United States.
Eligible participants will (1) endorse a desire for less pain, (2) indicate an interest in taking a health and wellness product to potentially help relieve their pain, and (3) express acceptance in taking a product and not knowing its formulation until the end of the study.
Participants with known liver or kidney disease, heavy drinkers, and those who report they are pregnant, trying to become pregnant, or breastfeeding will be excluded. Those taking certain medications will be excluded.
Self-reported data are collected electronically from eligible participants over 5 weeks. Participant reports of health indicators will be collected during baseline, throughout the active period of study product use, and in a final survey. All study assessments will be electronic; there are no in-person visits or assessments for this real-world evidence study
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Control 1 | Placebo Comparator | Relief Product Form 1 - control |
|
| Active Product 1.1 | Experimental | Relief Product Form 1 - active product 1 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Relief Study Product Usage | Dietary Supplement | Participants instructed to use study product daily as directed for a period of 4 weeks |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in pain interference | Mean difference in pain interference score as assessed by Patient Reported Outcome Measurement System (PROMIS) Pain Interference 6A [scale 6-30; with higher scores corresponding to greater pain interference] | 4 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Change in neuropathic pain | Mean difference in neuropathic pain score as assessed by PROMIS Neuropathic Pain 5A [scale 5-25; with higher scores corresponding to greater neuropathic pain] | 4 weeks |
| Change in nociceptive pain |
| Measure | Description | Time Frame |
|---|---|---|
| Change in energy (fatigue) | Mean difference in fatigue score as assessed by PROMIS Fatigue 4A [scale 4-20; with higher scores corresponding to greater fatigue] | 4 weeks |
| Change in cognitive function |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Emily K. Pauli, PharmD | Radicle Science Inc. | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Radicle Science, Inc | Del Mar | California | 92014 | United States |
Not provided
| Label | URL |
|---|---|
| Radicle Science, Inc | View source |
Not provided
Data will not be shared with researchers outside of Radicle Collaborators on this study.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010146 | Pain |
| D059226 | Nociceptive Pain |
| D009437 | Neuralgia |
| ID | Term |
|---|---|
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D010523 | Peripheral Nervous System Diseases |
Not provided
Not provided
Participants will be stratified based on gender at birth then randomized to one of the study arms
Not provided
Not provided
The investigator is blinded to the participants assigned study products. Participants are blinded to the study product they received.
Mean difference in nociceptive pain score as assessed by PROMIS Nociceptive Pain 5A [scale 5-25; with higher scores corresponding to greater nociceptive pain]
| 4 weeks |
| Change in pain intensity | Mean difference in pain intensity score as assessed by PROMIS Pain Intensity 1A [scale 1-10; with 0 being 'No pain' and 10 being 'The worst imaginable pain'] | 4 weeks |
| Change in feelings of anxiety | Mean difference in anxiety score as assessed by PROMIS Anxiety 4A [scale 4-20; with higher scores corresponding to more severe anxiety] | 4 weeks |
| Change in sleep disturbance | Mean difference in sleep disturbance score as assessed by PROMIS Sleep Disturbance Form 4A [scale 4-20; with higher scores corresponding to more severe sleep disturbance] | 4 weeks |
| Minimal clinically important difference (MCID) in pain interference | Likelihood of experiencing MCID in pain interference score as assessed by PROMIS Pain Interference 6A | 4 weeks |
| Minimal clinically important difference (MCID) in neuropathic pain | Likelihood of experiencing MCID in neuropathic pain score as assessed by PROMIS Neuropathic Pain 5A | 4 weeks |
| Minimal clinically important difference (MCID) in nociceptive pain | Likelihood of experiencing MCID in nociceptive pain score as assessed by PROMIS Nociceptive Pain 5A | 4 weeks |
| Minimal clinically important difference (MCID) in pain intensity | Likelihood of experiencing MCID in pain intensity score as assessed by PROMIS Pain Intensity 1A | 4 weeks |
Mean difference in cognitive function score as assessed by PROMIS Cognitive Function 4A [scale 4-20; with higher scores corresponding to greater cognitive function]
| 4 weeks |
| Change in emotional distress | Mean difference in emotional distress score as assessed by PROMIS Emotional Distress- Depression 4A [scale 4-20; with higher scores corresponding to greater levels of emotional distress] | 4 weeks |
| Change in sexual interest | Mean difference in sexual interest as assessed by PROMIS Sexual Interest 2.0 [scale 2-10; with higher scores corresponding to greater interest in sexual activity] | 4 weeks |
| D009468 | Neuromuscular Diseases |
| D009422 | Nervous System Diseases |